NEW HAVEN, Conn.--(BUSINESS WIRE)--
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) said today that its Board of
Directors and Elliott have agreed to work collaboratively to promptly
identify a new member to join the Alexion Board. Alexion announced in
November that it had a search underway to fill an open Board seat and is
seeking candidates who represent a range of backgrounds, perspectives,
skills, and expertise, with an emphasis on maintaining a diverse Board.
David Brennan, Chairman of Alexion's Board of Directors, said, "This
agreement is in line with our ongoing efforts to maintain active and
constructive dialogue with all of our shareholders and to identify a new
board member with a proven track record of building value. We have been
actively working to expand and diversify our Board, and we welcome input
from Elliott to identify a strong director candidate to further
strengthen Alexion's Board."
An Elliott spokesperson stated, "Elliott is pleased to reach agreement
with Alexion to identify a new independent director to join the
Company's Board of Directors. We are encouraged by actions taken under
Ludwig's leadership to improve financial performance and re-set
Alexion's strategy. Enhancing the strength of the Board is another step
toward maximizing value creation for all shareholders."
Alexion is a global biopharmaceutical company focused on serving
patients and families affected by rare diseases through the innovation,
development and commercialization of life-changing therapies. Alexion is
the global leader in complement inhibition and has developed and
commercializes the first and only approved complement inhibitor to treat
patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical
hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR)
antibody-positive generalized myasthenia gravis (gMG). In addition,
Alexion has two highly innovative enzyme replacement therapies for
patients with life-threatening and ultra-rare metabolic disorders,
hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). As
the leader in complement biology for over 20 years, Alexion focuses its
research efforts on novel molecules and targets in the complement
cascade, and its development efforts on the core therapeutic areas of
hematology, nephrology, neurology, and metabolic disorders. This press
release and further information about Alexion can be found at: www.alexion.com.
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements often include words such as "anticipate,"
"believe," "expect," "will," or similar expressions. Forward-looking
statements are subject to factors that may cause Alexion's results and
plans to differ from those expected, including the risks set forth from
time to time in Alexion's filings with the U.S. Securities and Exchange
Commission, including but not limited to the risks discussed in
Alexion's Quarterly Report on Form 10-Q for the period ended September
30, 2017 and in our other filings with the U.S. Securities and Exchange
Commission. Alexion does not intend to update any of these
forward-looking statements to reflect events or circumstances after the
date hereof, except when a duty arises under law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180102005790/en/
Alexion Pharmaceuticals, Inc.
Kim Diamond, 475-230-3775
Director, Corporate Communications
Ridloff, CFA, 475-230-3601
Vice President, Investor Relations
Director, Investor Relations
Source: Alexion Pharmaceuticals, Inc.
News Provided by Acquire Media